Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
EP4 agonist
8691857 EP4 agonist
Patent Drawings:

Inventor: Murata, et al.
Date Issued: April 8, 2014
Application:
Filed:
Inventors:
Assignee:
Primary Examiner: Barker; Michael
Assistant Examiner:
Attorney Or Agent: Leydig, Voit & Mayer, Ltd.
U.S. Class: 514/382; 548/252
Field Of Search: ;514/381; ;514/469; ;548/250; ;549/305; ;549/465
International Class: A61K 31/41
U.S Patent Documents:
Foreign Patent Documents: 2405255; 1 988 087; 02-500371; 07-324081; 07-330752; 10-194992; 2004-256547; WO 89/00563; WO 97/03973; WO 97/17974; WO 98/13356; WO 98/41209; WO 99/66913; WO 00/24727; WO 03/103664; WO 2008/116670; WO 2010/029925
Other References: Abramovitz et al., Biochimica et Biophysica Acta, 1483: 285-293 (2000). cited by applicant.
Angulo et al., Br. J. Pharmacol., 136: 23-30 (2002). cited by applicant.
Arakawa et al., Japanese J. Clin. Med., 42(1): 89-94 (1984). cited by applicant.
Chang et al., Prostaglandins, 53: 83-90 (1997). cited by applicant.
Fabricius et al., J. Immunology, 184: 677-684 (2010). cited by applicant.
Foudi et al., British Journal of Pharmacology, 154: 1631-1639 (2008). cited by applicant.
Graham et al., Expert Opin. Investig. Drugs., 18(6): 749-766 (2009). cited by applicant.
Grigsby et al., Biology of Reproduction, 75: 297-305 (2006). cited by applicant.
Hishikari et al., Cardiovascular Research, 81: 123-132 (2009). cited by applicant.
Hori et al., Neuroscience, 160: 813-819 (2009). cited by applicant.
Hristovska et al., Hypertension, 50: 525-530 (2007). cited by applicant.
Jiang et al., The Journal of Pharmacology and Experimental Therapeutics, 320(1): 22-28 (2007). cited by applicant.
Jiang et al., World Journal of Gastroenterology, 15(41): 5149-5156 (2009). cited by applicant.
Jones et al., British Journal of Pharmacology, 134: 313-324 (2001). cited by applicant.
Kabashima et al., The Journal of Clinical Investigation, 109(7): 883-893 (2002). cited by applicant.
Kiriyama et al., British Journal of Pharmacology, 122: 217-224 (1997). cited by applicant.
Konturek et al., Prostaglandins, 28(4): 443-453 (1984). cited by applicant.
Kuzumoto et al., Transplant Proceedings, 37: 422-424 (2005). cited by applicant.
Lai et al., Am. J. Respir. Crit. Care Med., 178: 188-196 (2008). cited by applicant.
Li et al., Neuroscience Letters, 438: 210-215 (2008). cited by applicant.
Minami et al., Journal of Biological Chemistry, 283(15): 9692-9703 (2008). cited by applicant.
Nitta et al., Scand. J. Immunol., 56: 66-75 (2002). cited by applicant.
Patani et al., Chem Rev., 96(8): 3147-3176 (1996). cited by applicant.
Prasanna et al., Exp. Eye Res., 89: 608-617 (2009). cited by applicant.
Sakai et al., Kobe J. Med. Sci., 47: 35-45 (2001). cited by applicant.
Schaaf et al., J. Med. Chem., 22 (11): 1340-1346 (1979). cited by applicant.
Sekiguchi et al., Spine, 31(8): 869-872 (2006). cited by applicant.
Shi et al., J. Immunology, 184: 7207-7218 (2010). cited by applicant.
Torii et al., Biochem. Biophys. Res. Commun., 290: 696-700 (2002). cited by applicant.
Vukicevic et al., Kidney Int., 70: 1099-1106 (2006). cited by applicant.
Wermuth, ed., Saishin Soyaku Kagaku, 1.sup.st edition, vol. 1, pp. 235-271 (Technomics, Inc., 2008). cited by applicant.
Wermuth, ed., The Practice of Medicinal Chemistry, 1.sup.st edition, part III, chapter 13, pp. 203-237 (Academic Press, 1996). cited by applicant.
Yoshida et al., Proc. Natl. Acad. Sci. USA., 99(7): 4580-4585 (2002). cited by applicant.
Zushi et al., Therapeutic Res., 18(Supp. 1): 138-143 (1997). cited by applicant.
Japanese Patent Office, International Search Report in International Patent Application No. PCT/JP2011/055411 (Apr. 26, 2011). cited by applicant.
Japanese Patent Office, International Search Report in International Patent Application No. PCT/JP2009/065690 (Oct. 13, 2009). cited by applicant.
Echeverria et al., European Journal of Neuroscience, 22: 2199-2206 (2005). cited by applicant.
Figiel, Acta Neurobiol. Exp., 68: 526-534 (2008). cited by applicant.
Ikeda-Matsuo et al., Journal of Neuroimmunology, 238: 34-43 (2011). cited by applicant.
Lee et al., Journal of Neuroimmunology, 155: 21-31 (2004). cited by applicant.
Liang et al., The Journal of Clinical Investigation, 121(11): 4362-4371 (2011). cited by applicant.
Mei-Ling et al., Neuroscience Letters, 508: 31-36 (2012). cited by applicant.
Milatovic et al., NeuroToxicology, 32: 312-319 (2011). cited by applicant.
Miyagishi et al., Journal of Pharmacological Sciences, 121: 347-350 (2013). cited by applicant.
Sugimoto et al., The Journal of Biological Chemistry, 282: 11613-11617 (2007). cited by applicant.
Zhen et al., Neurobiology of Aging, 33: 2215-2219 (2012). cited by applicant.









Abstract: Provided is a compound represented by the formula (1): ##STR00001## wherein R.sup.1 and R.sup.2 are each independently a hydrogen atom or a straight chain alkyl group having a carbon number of 1-3, R.sup.3 is a hydrogen atom, an alkyl group having a carbon number of 1-4, an alkoxyalkyl group, an aryl group, a halogen atom or a haloalkyl group, or a pharmaceutically acceptable salt thereof, which has, unlike known PGI.sub.2 analogs, a selective EP4 agonist action, and a medicament containing the compound, which is useful for the prophylaxis and/or treatment of immune diseases, diseases of the digestive tract, cardiovascular diseases, cardiac diseases, respiratory diseases, neurological diseases, ophthalmic diseases, renal diseases, hepatic diseases, bone diseases, skin diseases and the like.
Claim: The invention claimed is:

1. A method of treating osteoporosis in a subject, comprising administrating an effective amount of a compound of formula (1): ##STR00006## wherein R.sup.1 and R.sup.2are each independently a hydrogen atom or a straight chain alkyl group having a carbon number of 1 to 3, and R.sup.3 is a hydrogen atom, an alkyl group having a carbon number of 1 to 4, an alkoxyalkyl group, an aryl group, a halogen atom, or a haloalkylgroup, or a pharmaceutically acceptable salt thereof, as an active ingredient to a subject with osteoporosis, thereby treating osteoporosis in the subject.

2. A method of treating a bone fracture in a subject, comprising administrating an effective amount of a compound of formula (1): ##STR00007## wherein R.sup.1 and R.sup.2 are each independently a hydrogen atom or a straight chain alkyl grouphaving a carbon number of 1 to 3, and R.sup.3 is a hydrogen atom, an alkyl group having a carbon number of 1 to 4, an alkoxyalkyl group, an aryl group, a halogen atom, or a haloalkyl group, or a pharmaceutically acceptable salt thereof, as an activeingredient to a subject with a bone fracture, thereby treating the bone fracture in the subject.

3. A method of treating neuronal cell death in a subject, comprising administrating an effective amount of a compound of formula (1): ##STR00008## wherein R.sup.1 and R.sup.2 are each independently a hydrogen atom or a straight chain alkylgroup having a carbon number of 1 to 3, and R.sup.3 is a hydrogen atom, an alkyl group having a carbon number of 1 to 4, an alkoxyalkyl group, an aryl group, a halogen atom, or a haloalkyl group, or a pharmaceutically acceptable salt thereof, as anactive ingredient to a subject with neuronal cell death, thereby treating neuronal cell death in the subject.

4. A method of treating amyotrophic lateral sclerosis in a subject, comprising administrating an effective amount of a compound of formula (1): ##STR00009## wherein R.sup.1 and R.sup.2 are each independently a hydrogen atom or a straight chainalkyl group having a carbon number of 1 to 3, and R.sup.3 is a hydrogen atom, an alkyl group having a carbon number of 1 to 4, an alkoxyalkyl group, an aryl group, a halogen atom, or a haloalkyl group, or a pharmaceutically acceptable salt thereof, as anactive ingredient to a subject with amyotrophic lateral sclerosis, thereby treating amyotrophic lateral sclerosis in the subject.

5. A method of treating multiple sclerosis in a subject, comprising administrating an effective amount of a compound of formula (1): ##STR00010## wherein R.sup.1 and R.sup.2 are each independently a hydrogen atom or a straight chain alkyl grouphaving a carbon number of 1 to 3, and R.sup.3 is a hydrogen atom, an alkyl group having a carbon number of 1 to 4 an alkoxyalkyl group, an aryl group, a halogen atom, or a haloalkyl group, or a pharmaceutically acceptable salt thereof, as an activeingredient to a subject with multiple sclerosis, thereby treating multiple sclerosis in the subject.
Description:
 
 
  Recently Added Patents
Mobile target system
Focus detection device and imaging apparatus having the same
System for purifying air through germicidal irradiation and method of manufacture
Systems, computer programs, and methods for controlling costs of a healthcare practice
Continuous geospatial tracking system and method
Polymers derived from benzobis(silolothiophene) and their use as organic semiconductors
Techniques to manage communications resources for a multimedia conference event
  Randomly Featured Patents
Nickel hydrogen storage cell
Method for integrating anti-reflection layer and salicide block
Method of making a chiral stationary phase based on yohimbine
Process for the production of methomyl oxime
Wound dressings with electrically conductive layers
Fuel-cell systems operable in multiple modes for variable processing of feedstock materials and associated devices, systems, and methods
Molten material application machine
Control system for DC power transmission
Method for setting up a painting system in a predefined setup location
Hepatitis delta virus compositions and expression vectors